rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
6363
|
pubmed:dateCreated |
1983-3-24
|
pubmed:abstractText |
A double blind trial of three oral preparations given in single doses for the treatment of Schistosoma haematobium infection was carried out in schoolchildren; selection was biased towards those who excreted large quantities of eggs. Praziquantel 40 mg/kg was the most effective drug giving a greater than 97% reduction in egg output six months after treatment; combined treatment with niridazole 25 mg/kg and metrifonate 10 mg/kg gave a reduction of greater than 92% and metrifonate 10 mg/kg alone a reduction of greater than 86%. Fewer children continued to have moderate to heavy infections (excretion greater than 124 ova/10 ml urine) six months after treatment with praziquantel (5%) and the combined regimen (7%) than with metrifonate (16%). Though our findings show that praziquantel appears to be the most effective and convenient drug available for individuals with S haematobium infection, the combined regimen is a cheaper alternative for treatment where cost is important and parasitological cure not an essential objective.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-1035444,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-396053,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-396056,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-5308698,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-562074,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-697446,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-7008948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-7112663,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-718304,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-7324139,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-739160,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6401550-7458464
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0267-0623
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
5
|
pubmed:volume |
286
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
429-32
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:6401550-Administration, Oral,
pubmed-meshheading:6401550-Adolescent,
pubmed-meshheading:6401550-Child,
pubmed-meshheading:6401550-Clinical Trials as Topic,
pubmed-meshheading:6401550-Double-Blind Method,
pubmed-meshheading:6401550-Drug Combinations,
pubmed-meshheading:6401550-Female,
pubmed-meshheading:6401550-Hematuria,
pubmed-meshheading:6401550-Humans,
pubmed-meshheading:6401550-Isoquinolines,
pubmed-meshheading:6401550-Male,
pubmed-meshheading:6401550-Niridazole,
pubmed-meshheading:6401550-Praziquantel,
pubmed-meshheading:6401550-Schistosoma haematobium,
pubmed-meshheading:6401550-Schistosomiasis,
pubmed-meshheading:6401550-Trichlorfon,
pubmed-meshheading:6401550-Urinary Tract Infections
|
pubmed:year |
1983
|
pubmed:articleTitle |
Single dose oral treatment in urinary schistosomiasis: a double blind trial.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|